Acting by inhibiting EGF-induced receptor autophosphorylation and associated downstream anabolic pathways, anti-EGF nanobodies Ia1, L2–3.40 and IIIa3 completely blocked EGF-induced proliferation of squamous cell carcinoma cells in vitro. This evidence concerns the gene EGF and squamous cell carcinoma.